论文部分内容阅读
[目的]探讨解聚素—金属蛋白酶17(a disintegrin and metalloproteinase 17,ADAM17)在人脑胶质瘤的表达及临床意义。[方法]采用Western blot法检测胶质瘤组织中ADAM17蛋白的表达,并分析其与胶质瘤恶性程度的相关性。[结果]正常人脑组织中ADAM17呈微量表达,人脑胶质瘤中表达增多,且随着恶性程度的提高,表达也进一步增多。低度恶性组中ADAM17的表达是正常脑组织的1.9倍,高度恶性组中的表达是正常脑组织的5.0倍,是低度恶性组的2.8倍。[结论]ADAM17可能在胶质瘤的发生、发展中发挥着一定的作用,ADAM17的检测可有助于胶质瘤恶性度分级判断。
[Objective] To investigate the expression and clinical significance of disintegrin and metalloproteinase 17 (ADAM17) in human glioma. [Method] The expression of ADAM17 protein in glioma tissue was detected by Western blot and its correlation with malignant degree of glioma was analyzed. [Result] The expression of ADAM17 in normal human brain was slight, and it was increased in human glioma. With the increase of malignant degree, the expression of ADAM17 was further increased. The expression of ADAM17 in low grade malignant group was 1.9 times that in normal brain tissue, that in highly malignant group was 5.0 times that of normal brain tissue and 2.8 times that of low grade malignant group. [Conclusion] ADAM17 may play a role in the occurrence and development of glioma. The detection of ADAM17 may be helpful for the grading of malignant glioma.